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SHORT COMMUNICATION
Non-P-glycoprotein-mediated multidrug resistance with reduced EGF
receptor expression in a human large cell lung cancer cell line
J.G. Reeve, P.H. Rabbitts & P.R. Twentyman
MRC Clinical Oncology and Radiotherapeutics Unit, Medical Research Council Centre, Hills Road, Cambridge CB2 2QH, UK.
The pharmacological basis for in vitro multidrug resistance
(MDR) appears to be a reduced steady state accumulation of
drugs usually attributed to the over-production of membrane
P-glycoprotein (Riordan & Ling, 1985). This protein has
drug-binding properties (Cornwell et al., 1986; Safa et al.,
1986; Naito et al., 1988) and is thought to function as an
energy-dependent efflux pump (Willingham et al., 1986), a
contention supported by the observation that agents which
overcome multidrug resistance inhibit the drug binding-pro-
perties of P-glycoprotein and increase cellular accumulation
of drug (Cornwell et al., 1987; Safa et al., 1987; Naito &
Tsuruo, 1989). The frequency with which MDR is associated
with over-production of this membrane glycoprotein,
together with the ability of the mdr-l gene, encoding P-glyco-
protein, to confer MDR when transfected into drug sensitive
cells (Shen et al., 1986), indicates that a P-glycoprotein-
mediated drug transport mechanism is a major component of
the MDR phenotype in almost all cell lines examined to date.
Another MDR-associated protein alteration commonly ob-
served in MDR cell lines is hyperexpression of the cytosolic
calcium binding protein, sorcin/CP22 (Meyers & Biedler,
1981; Van der Bliek et al., 1986; Koch et al., 1986). The
functional role of this protein in the MDR phenotype is
unclear, as is the increase in EGF receptor number which has
been observed in selected MDR Chinese hamster and mouse
tumour cell lines (Meyers et al., 1986).
In view of the central role played by P-glycoprotein in
MDR in tissue culture, a number of studies have sought to
establish a role for this protein in clinical drug resistance.
Immunohistochemical studies and measurements of mdr-l
mRNA in tumour samples before and after chemotherapy
suggest that P-glycoprotein may have clinical significance in
selected tumours (Bell et al., 1985; Salmon et al., 1989;
Goldstein et al., 1989; Kanamaru et al., 1989; Rothenburg &
Ling, 1989; Lai et al., 1989). However, in many drug resis-
tant tumours, including those of the lung (Lai et al., 1989),
no evidence for over-production of P-glycoprotein has been
obtained. In this context it is interesting to note that one of
the very few in vitro derived MDR cell lines which fails to
over-produce P-glycoprotein was derived from a small cell
lung cancer cell line (Mirski et al., 1987).
The acquisition of the MDR phenotype in the absence of
over-expressed P-glycoprotein, often referred to as 'atypical'
MDR (Beck et al., 1987), clearly indicates the existence of
alternative biochemical pathways that lead to MDR. Such
mechanisms may be clinically relevant and an understanding
of the biochemical basis of this type of MDR will be facil-
itated greatly by the isolation of atypical MDR cell lines. In
an effort to gain insight into the molecular mechanisms of
drug resistance in human lung tumours, we have recently
derived MDR variants of both small cell lung cancer (SCLC)
and non-small cell lung cancer (NSCLC) cell lines (Twen-
tyman et al., 1986). All cell lines have been examined for the
expression of P-glycoprotein using the mdr-l specific cDNA
probe and the C219 mouse monoclonal antibody to P-glyco-
protein. While LX4, the MDR variant of SCLC cell line
NCI-H69, hyperexpresses P-glycoprotein (Reeve et al., 1989)
we here report that the MDR variant of large cell lung
carcinoma cell line, COR-L23, shows no evidence of P-glyco-
protein hyperexpression. Furthermore, in contrast to pre-
vious reports for hamster and mouse MDR cell lines (Meyers
et al., 1986), the MDR variant of COR-L23 shows a marked
reduction in EGF receptor number.
Full details of the derivation of the MDR variant of
COR-L23 are given elsewhere (Twentyman et al., 1986).
Throughout this report the parent COR-L23 line is referred
to as L23/P and the resistant variant, COR-L23/R, as L23/R.
The resistant variant was derived by growth of the parent
line in increasing concentrations of adriamycin (ADM) to
0.2,g ml-'. Drug sensitivity to vincristine (VCR) and colchi-
cine (COL) was determined using a tetrazolium dye reduction
assay (MTT) as previously described (Twentyman, 1988). It
can be seen from Table I that L23/R is fully cross-resistant to
VCR and COL. In addition, it has been shown previously
that L23/R shows reduced cellular accumulation of ADM
compared to the parent line (Twentyman et al., 1986).
For the immunodetection of P-glycoprotein, microsomal
membranes were prepared from cells in exponential growth
(Riordan & Ling, 1979) and membrane proteins were subject-
ed to SDS-gel electrophoresis according to Debenham et al.
(1982). For the immunodetection of CP22, cytosolic proteins
were prepared as previously described (Koch et al., 1986) and
were electrophoresed on a discontinuous gel system accord-
ing to Laemmli (1970). Transfer of resolved proteins from
gels to nitrocellulose filter paper was as described by Towbin
et al. (1979). Protein transfer was performed for 4 h at 4°C at
a constant current of 0.5 A using a solution containing
0.0125 M Tris, 0.2 M glycine (pH 8.5) and 20% methanol as
the electrode buffer. After transfer, additional protein bind-
ing sites on nitrocellulose were blocked by incubation of the
paper overnight in 5 mM EDTA, 0.25% gelatin, 0.01 M
NaN3, 0.15 M NaCl, 0.05 M Tris-base, and 0.05% Nonidet
P40 (NGA buffer). The paper was then incubated overnight
at 4°C with either monoclonal antibody C219 (Kartner et al.,
1985), or affinity purified, monospecific antibody to CP22
(kindly supplied by Gordon Koch, Laboratory of Molecular
Biology, MRC Centre, Cambridge), diluted in NGA buffer.
'25I-labelled rabbit anti-mouse IgGI was used to detect mouse
monoclonal antibody to P-glycoprotein. For rabbit anti-
CP22 antibody, 125i-protein A autoradiography was used to
visualise antibody binding to protein bands.
Table I Drug sensitivities of L23/P and L23/R
ADM VCR COL
L23/P 0.017 0.0009 0.0016
L23/R 0.34 0.029 0.016
RFa 22.7 33.6 9.8
(8.6) (13.4) (0.9)
Values given are ID50 intsgmlh in the MTT assay and are the means
ofthreedeterminations forADM andVCR and twodeterminations for
COL. aRF, resistance factor =ID50(L23/R)/ID50(L23/P). Figures in
parentheses are standard deviations.
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Full details of the procedures used for the detection of
P-glycoprotein mRNA by Northern blot analysis using the
mdr-I specific cDNA probe, pHDR105 (kindly donated by
Dr I. Roninson, Centre for Genetics, University of Illinois
College of Medicine at Chicago) (Roninson et al., 1986), are
given elsewhere (Reeve et al., 1989). Northern blot analysis
of sorcin and EGF receptor gene expression was performed
similarly using the sorcin cDNA probe cp8 (Van der Bliek et
al., 1986) and a human EGF receptor cDNA probe (kindly
donated by Dr M. Waterfield, Imperial Cancer Research
Fund Laboratories, Lincoln's Inn Fields, London) respect-
ively.
EGF receptor binding assays were carried out according to
the procedures described by Das et al. (1977). Briefly con-
fluent monolayer cultures of L23/P and L23/R (2 x 105 cells
per dish) were washed and 1 ml of Hanks' Balanced Salt
Solution (HBSS) containing 0.1% bovine serum albumin
(BSA) was added to each dish. '25I-EGF (0.01-1.0 nM) was
added in the presence or absence of 100 nM unlabelled EGF
for 60 min at 37°C and 6 h at 4°C. Unbound radioactivity
was removed by five rapid washes in ice-cold HBSS/0.1%
BSA. Washed monolayers were solubilised in I ml 0.5 M
NaOH and counted in a y counter.
Immunostaining of cytospin preparations of L23/P and
L23/R using the anti-EGF receptor monoclonal antibody,
225 (kindly supplied by Dr J. Mendelsohn, Department of
Medicine, Sloan-Kettering Cancer Centre, New York) (Sato
et al., 1983) was carried out as previously described (Reeve et
al., 1988). Briefly, unfixed cells were incubated for 30min
at 37°C with monoclonal antibody 225 (1 tgml-'). After
washing, cells were reacted with FITC-conjugated rabbit
anti-mouse 1 gG (Dako Ltd, High Wycombe, Bucks),
washed, mounted and viewed with an Olympus fluorescence
microscope.
Figure la,b shows that, in contrast to LX4, the MDR
variant of SCLC cell line NCI-H69, no evidence of P-glyco-
protein hyperexpression was observed in L23/R. Figure 2
shows that while the sorcin/CP22 gene is clearly expressed
in the parent line, increased expression does not occur in
L23/R. Northern blot analysis using the cp8 cDNA probe
confirmed this result (data not shown). On the basis of these
findings it appears that neither P-glycoprotein nor the cal-
cium binding protein sorcin/CP22 are components of the
MDR phenotype of this NSCLC cell line.
EGF receptors are generally expressed on NSCLC tumours
(Haeder et al., 1988), and in view of an earlier report of
increases in EGF receptor numbers coincident with the
development of MDR (Meyers et al., 1986), EGF receptor
binding assays and immunocytochemical studies were under-
taken to investigate EGF receptor expression in L23/P and
L23/R. Scatchard plot analyses of binding data from repre-
sentative experiments carried out at 0°C are shown in Figure
3. Non-specific binding was consistently less than 3%. The
Scatchard plots for L23/P at 37°C and 0°C were curvilinear,
perhaps indicating the expression of two classes of receptor
having different affinities for EGF. Because of the difficulties
inherent in interpreting curvilinear Scatchard plots, estima-
tions of receptor numbers are potentially inaccurate. How-
ever, for L23/P extrapolation of the curve to the abscissa
suggests that the parent line has approximately 300,000
receptor sites per cell. This value is within the range reported
for EGF receptor expression in other NSCLC cell lines
(Haeder et al., 1988). The linear Scatchard plot obtained
for L23/R perhaps indicates that the class of high affinity
receptors expressed by the parent line have been lost. Extra-
polation of the data to the abscissa suggests that L23/R has
approximately 100,000 receptor sites per cell.
Confirmation of the apparent reduction in EGF receptor number in L23/R compared to the parent line was obtained
from immunocytochemical studies with a monoclonal anti-
body to the EGF receptor. Figure 4 shows that the reactivity of the drug resistant variant with the EGF receptor antibody is considerably reduced compared to the parent line.
Northern blot analysis of EGF receptor gene expression in
L23/P and L23/R revealed a significantly weaker hybridisa-
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Figure I a, Immunodetection of P-glycoprotein (arrow) by mono-
clonal antibody C219 in parent SCLC cell line NCI-H69 (H69/P),
LX4, the MDR variant of H69/P, the parent COR-L23 (L23/P)
oell line and its MDR variant, L23/R. b, Expression of mdr I
sequences (arrow) in H69/P, LX4, L23/P and L23/R. Northern
blot of RNA hydridised with the mdr 1 specific probe, pHDR105.
The size of the RNA transcript which is detected in LX4 but not
L23/R is approximately 5 kb. Equal loading was confirmed by
reprobing with an actin cDNA probe (PRT 3) (kindly supplied by
Dr J. Rogers, Laboratory of Molecular Biology, Cambridge, UK).
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Figure 2 Immunodetection of sorcin/CP22 (arrow) in L23/P and
L23/R by a monospecific affinity purified antibody to sorcin/
CP22.NON-P-GLYCOPROTEIN-MEDIATED MDR 853
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Figure 3 Scatchard analyses of '25I-labelled EGF binding at 0°C
to L23/P (m) and L23/R (m) cells. Inset: representative binding
curves.
Figure 4 Reactivity of L23/P cells (upper panel) and L23/R cells
(lower panel) with monoclonal antibody 225 directed against the
EGF receptor.
tion signal in the drug resistant variant compared to parent
line (Figure 5). This suggests that the reduction in receptor
numbers observed in L23/R results from reduced expression
of the EGF receptor gene rather than from changes in the
cellular processing of the receptor or in receptor binding
capacity.
The finding that P-glycoprotein can bind drug to which the
cells are resistant (Cornwell et al., 1986; Safa et al., 1986;
Naito et al., 1988) supports a functional role of this protein
in modulating cellular drug levels. However, the findings of
the present report show that hyperexpression of P-glyco-
protein is not responsible for the reduced cellular accumula-
tion of drug exhibited by L23/R. Recently it has been shown
that human leukaemia HL60 cells selected for resistance
Figure 5 Expression of EGF receptor sequences (large arrow) in
L23/R and L23/P. The smaller arrow indicates the position of
actin sequences which confirm equal loading of RNA in the two
tracks.
to ADM are also multidrug resistant and defective in drug
accumulation but do not hyperexpress P-glycoprotein
(McGrath et al., 1987). Analysis of these cells has demon-
strated the expression of a surface membrane protein, P150,
which is phosphorylated only in the drug resistant variant
(McGrath & Center, 1988). Studies are in progress to
examine the expression and phosphorylation of this protein
in L23/R.
Other potential components of the atypical MDR pheno-
type expressed by L23/R may include changes in protein
kinase C activity (Chabner, 1986), aberrant DNA topoiso-
merase II (Glisson et al., 1986) and altered expression of
phase I and II drug metabolising enzymes (Ivy et al., 1987).
Preliminary studies suggest that cellular capacity for drug-
induced cross-linking of topoisomerase II to DNA is reduced
in L23/R compared to the parent line (P.J. Smith, personal
communication).
While no evidence was obtained in the present study for
changes in intracellular sorcin/CP22 coincident with the
development of MDR, acquisition of the MDR phenotype
by L23/P is associated with a significant reduction in the
number and possibly the affinity of EGF receptors. The
significance of changes in EGF receptor expression in drug
resistant cell lines is not clear. Although a previous report
describes increases in EGF receptor numbers in selected
MDR cell lines, an investigation of whether high levels of
EGF receptor per se would render a cell intrinsically drug
resistant showed that cells expressing high levels of EGF
0)12
0.10
a1)
0
m
c:.
C,)
N
-J
0L
.C
N
0.08
0.06
0.04
0.02
o854 J.G. REEVE et al.
receptor were more drug sensitive than control cells (Meyers
et al., 1986). Hence the reduction in EGF receptor number
reported here for L23/R may indeed be a phenotypic change
associated with the development of drug resistance in this cell
line. Southern blot analyses show that the EGF receptor gene
is not amplified in L23/P (data not shown). Hence reduced
EGF receptor expression in L23/R has not resulted from
selection of cells with fewer EGF receptor gene copies than
the parent line. Investigations are in progress to investigate
the apparent decrease in EGF receptor gene expression in
L23/R. Studies to date indicate that reduced EGF receptor
number is stable and not dependent on the presence of
ADM. We are currently conducting experiments to inves-
tigate the proliferative effects of exogenous EGF in L23/P
and L23/R, particularly with respect to the effect of this
growth factor on the cytotoxicity of topoisomerase Il-inter-
active drugs in the two lines.
The authors thank Dr G.L.E. Koch (Laboratory of Molecular Bio-
logy, MRC Centre, Cambridge, UK) for Western blot analysis of
CP22 expression. The authors also gratefully acknowledge the excel-
lent technical assistance of Ms J.A. Payne and Mrs K.A. Wright.
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